RCS - Allergy Therapeutics - Allergy Therapeutics presents progress at AAAAI

Allergy TherapeuticsAnnouncement

26/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260226:nRSZ4334Ua&default-theme=true

RNS Number : 4334U  Allergy Therapeutics PLC  26 February 2026

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company" or "Group")

 

Allergy Therapeutics presents further scientific progress in its pollen and
food-allergy research portfolio at the 2026 AAAAI Annual Meeting

 

26 February 2026 - Allergy Therapeutics plc (AIM: AGY), the fully integrated
commercial biotechnology company specialising in allergy immunotherapies,
today announces that it will be sharing key scientific findings from across
its research portfolio at the 2026 American Academy of Allergy, Asthma &
Immunology (AAAAI) Annual Meeting (https://annualmeeting.aaaai.org/) , taking
place in Philadelphia, Pennsylvania from tomorrow, 27 February to 2 March
2026.

The 2026 AAAAI Annual Meeting is a premier conference in the field of allergy,
asthma and immunology, hosted by the American Academy of Allergy, Asthma &
Immunology (AAAAI), a leading membership organisation of more than 7,000
allergists/immunologists and related professionals around the world.

Among its three posters being presented, Allergy Therapeutics will share:

•     Positive biomarker and clinical data demonstrating that Grass MATA
MPL effectively induces tolerogenic properties through modulation of both
humoral and cellular immune responses, with a statistically significant
improvement of −22.5% in Combined Symptom Medication Score (P<0.00004)
compared to placebo across the G306 and G309 Phase III clinical trials,
supporting the Group's short-course subcutaneous allergen-specific
immunotherapy (SCIT) as an effective and well-tolerated treatment for seasonal
allergic rhinitis

•     Supportive short-term blinded safety data from the first cohort of
190 paediatric participants in the G308 Phase III long-term adaptive trial
investigating Grass MATA MPL in children and adolescents with grass
pollen-induced seasonal allergic rhinitis, demonstrating a benign safety
profile and a low trial discontinuation rate

•     Positive safety, tolerability and interim biomarker data from the
Phase I/IIa PROTECT clinical trial of VLP Peanut, the Group's innovative,
short-course peanut allergy immunotherapy candidate, in healthy and
peanut-allergic adults, confirming its potential as a promising therapeutic
candidate for peanut allergy treatment

Manuel Llobet, Chief Executive Officer at Allergy Therapeutics, said: "The
three presentations at this year's AAAAI Annual Meeting reflect the breadth
and momentum of our clinical portfolio. The combined biomarker and efficacy
data across two Phase III trials reinforce the compelling profile of Grass
MATA MPL as a differentiated short-course immunotherapy, while the supportive
paediatric safety data from G308 further extend the evidence base into a
younger patient population. In parallel, the continued progress of our VLP
Peanut programme demonstrates the versatility of our platform approach.
Following the recent regulatory approval of Grass MATA MPL in Germany, the
first subcutaneous grass pollen immunotherapy to be authorised under the TAV
framework, these data mark another important step in our mission to deliver
innovative, disease-modifying therapies for allergy sufferers worldwide."

The complete list of Allergy Therapeutics-sponsored abstracts accepted by
AAAAI for presentation are available on the Group's website.

No new material price sensitive information will be disclosed on Allergy
Therapeutics at the 2026 AAAAI Annual Meeting.

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker

Nigel Birks - Life Science Specialist Sales

+44 (0)20 7220 0500

 

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@icrhealthcare.com

 

Notes for editors:

 

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapies that have the potential to
cure disease. The Group sells proprietary and third-party products from its
subsidiaries and branches in nine major European countries and via
distribution agreements in an additional four countries. For more information,
please see www.allergytherapeutics.com (http://www.allergytherapeutics.com) .

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAKZGZZNKFGVZM



            Copyright 2019 Regulatory News Service, all rights reserved